NEOVACS (ALNEV.PA) Stock Overview
EPA:ALNEV - FR0014010856 - Common Stock
ALNEV.PA Key Statistics, Chart & Performance
The current stock price of ALNEV.PA is 0.59 EUR. In the past month the price decreased by -34.3%. In the past year, price decreased by -100%.
ALNEV.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 20.04 | 321.87B | ||
| 1ABBV.MI | ABBVIE INC | 19.56 | 314.07B | ||
| AMG.DE | AMGEN INC | 12.96 | 130.61B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 14.78 | 122.10B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.55 | 119.87B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.38 | 87.15B | ||
| ARGX.BR | ARGENX SE | 82.38 | 37.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.61B | ||
| IDP.DE | BIOGEN INC | 8.82 | 17.76B | ||
| 0QF.DE | MODERNA INC | N/A | 7.98B | ||
| 1MRNA.MI | MODERNA INC | N/A | 7.96B | ||
| 1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B |
Related stock screener links
About ALNEV.PA
Company Profile
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 20 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Company Info
NEOVACS
14 Rue De La Republique
Suresnes ILE-DE-FRANCE FR
Employees: 22
Phone: 33153109300
NEOVACS / ALNEV.PA FAQ
What is the stock price of NEOVACS today?
The current stock price of ALNEV.PA is 0.59 EUR. The price increased by 0.68% in the last trading session.
What is the ticker symbol for NEOVACS stock?
The exchange symbol of NEOVACS is ALNEV and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ALNEV.PA stock listed?
ALNEV.PA stock is listed on the Euronext Paris - Matif exchange.
What is NEOVACS worth?
NEOVACS (ALNEV.PA) has a market capitalization of 283.20K EUR. This makes ALNEV.PA a Nano Cap stock.
How many employees does NEOVACS have?
NEOVACS (ALNEV.PA) currently has 22 employees.
Should I buy NEOVACS (ALNEV.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALNEV.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALNEV.PA, evaluating the profitability, health, valuation and growth aspects
- NEOVACS (ALNEV.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEOVACS (ALNEV.PA) Sales and EPS estimates to see what analysts future expectations are.
- NEOVACS (ALNEV.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEOVACS (ALNEV.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEOVACS (ALNEV.PA) Stock Chart to make your own analysis
- NEOVACS (ALNEV.PA) Latest news and press-releases to stay up to date.
Does NEOVACS (ALNEV.PA) stock pay dividends?
ALNEV.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of NEOVACS (ALNEV.PA)?
NEOVACS (ALNEV.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-33334.67).
ALNEV.PA Technical Analysis
ALNEV.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALNEV.PA. Both the profitability and financial health of ALNEV.PA have multiple concerns.
ALNEV.PA Financial Highlights
Over the last trailing twelve months ALNEV.PA reported a non-GAAP Earnings per Share(EPS) of -33334.67. The EPS increased by 64.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -149.13% | ||
| ROE | -182.23% | ||
| Debt/Equity | 0.01 |